16 results about "Luteinizing hormone" patented technology

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

The sustained-release formulation of this invention, with its increased initial release, exhibits a rapid release effect within 24 hours after administration, followed by a sustained-release effect, thus simultaneously achieving both prolonged efficacy and rapid initial release. The sustained-release formulation of this invention, containing microspheres of leuprorelin, possesses excellent bioavailability and has been proven safe in humans; therefore, it can be effectively and safely used to treat various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer, and central precocious puberty.

This invention discloses a novel class of peptides for targeted cancer therapy and their corresponding drug or fluorescent dye conjugates, belonging to the field of biomedical technology. These peptides are designed based on the optimized structure of natural LHRH-III, enabling them to specifically bind to and efficiently internalize into tumor cells overexpressing luteinizing hormone-releasing hormone receptor (LHRH-R). After fluorescent conjugation, their targeting ability against 4T1 cells is comparable to that of the classic peptide [D-Lys]. 6 The [-LHRH-I] peptide exhibits comparable to or superior performance and significantly improves cellular internalization efficiency. In vivo distribution studies have shown that its liver accumulation is significantly reduced compared to the control group, effectively lowering the risk of hepatotoxicity. Furthermore, by conjugating the targeting peptide with antitumor drugs (such as camptothecin or doxorubicin) via disulfide linkers, the resulting peptide-drug conjugates (PDCs) demonstrate excellent responsive drug release characteristics and good in vitro and in vivo antitumor activity. The peptides and conjugates provided by this invention have potential application value in cancer targeted therapy and diagnosis with high specificity and low toxicity.

The invention relates to the technical field of livestock breeding biology, and discloses a method for promoting porcine ovary granular cell proliferation, which comprises the following steps: adding a porcine follicular fluid exosome into a porcine ovary granular cell culture system, and acting for a certain time at an effective concentration, so as to improve the proliferation activity of granular cells. After the exosome treatment, the apoptosis rate of granular cells can be reduced, the cell survival rate can be improved, and the granular cells can be promoted to secrete steroid hormones, including the estradiol level and the expression of progesterone synthetase. Cell experiments prove that the follicular fluid exosome can effectively improve the activity of granular cells, promote the process of a cell cycle, inhibit cell apoptosis and remarkably enhance the synthesis capacity of steroid hormones such as estradiol and progesterone, and a new intervention strategy is provided for improving follicular development and reproductive performance of sows.

This invention relates to the field of biomedical technology, and particularly to a specific LH blocking agent and its application in a β-HCG detection kit. The light chain amino acid sequence of the specific luteinizing hormone IgG antibody (LH-IgG antibody) of this invention is shown in SEQ ID NO.1, the heavy chain amino acid sequence is shown in SEQ ID NO.2, the light chain nucleotide sequence is shown in SEQ ID NO.3, and the heavy chain nucleotide sequence is shown in SEQ ID NO.4. This invention's LH antibody blocking agent is a self-developed product specifically designed for β-HCG detection, effectively removing interfering substances in serum. Using this LH antibody blocking agent significantly improves reagent performance, reduces false positive rates, and ensures the sensitivity and accuracy of the detection.

The application belongs to the technical field of aquaculture, and particularly relates to a water temperature-hormone synergistically regulated aquaculture population breeding and hatching method and application. The growth regulator is butyric acid or sodium butyrate. The growth regulator is used to enhance the breeding promotion effect of luteinizing hormone-releasing hormone or its analogs. The breeding promotion refers to promoting the growth of oocytes, promoting yolk accumulation, shortening the ovarian development cycle, and improving the egg production rate. It is found and verified for the first time that butyric acid and its sodium salt can enhance the breeding promotion effect of luteinizing hormone-releasing hormone.

The invention belongs to the technical field of biomacromolecule separation and purification, and particularly relates to an LH antibody affinity chromatography column as well as a preparation method and application thereof. According to the key principle of antigen-antibody combination, an NHS (N-hydroxysuccinimide) group is activated by an NHS 4FF chromatography filler, and then an LH antibody is combined to serve as a ligand to prepare the LH antibody affinity chromatography filler. By using the LH antibody affinity chromatography filler, the high-purity urofollicle-stimulating hormone (pFSH) is prepared from a drug raw material menotrophin (HMG) through 30 KD ultrafiltration. The result of the embodiment shows that the specific activity of high-purity urofollicle-stimulating hormone (pFSH) prepared by using the LH antibody affinity chromatography filler is greater than 15000 IU / mg protein, the ratio of LH to FSH is less than 0.05: 100.00, impurities such as impure protein are less, luteinizing hormone (LH) is more completely removed, and the product is safer and more efficient.

The application relates to the field of biotechnology, and discloses a culture medium system for maintaining and directionally inducing pluripotency of embryonic stem cells and application thereof. The culture medium comprises the following components in mass fractions: human insulin: 8-12 parts; tetramethylene diamine: 0.5-0.8 parts; luteinizing hormone: 0.2-0.5 parts; vitamin mixture: 1-2 parts; bovine serum albumin: 2-4 parts; sodium bicarbonate: 0.5-1.0 parts; antibiotic mixture: 0.2-0.4 parts; biotin: 1-2 parts; bone morphogenetic protein: 0.5-1.0 parts; and magnesium ethylenediaminetetraacetate: 0.1-0.2 parts. The application constructs a multi-factor regulation system, combines a signal inhibition, a three-dimensional support and a metabolic regulation module, realizes stable maintenance of pluripotency of embryonic stem cells, significantly improves culture uniformity, structural support and anti-differentiation capacity, and breaks through the technical bottleneck of a traditional system in terms of induction efficiency and stability.

The invention belongs to the technical field of construction of cell models, and particularly relates to a method for constructing a hyperuricemia testicular interstitial cell model. Comprising the following steps: (1) selecting an 8-week-old male C57BL / 6 mouse, dissecting, collecting testis, removing testis albuginea, cutting into fragments, digesting by utilizing collagenase IV, filtering, centrifuging, discarding supernatant, diluting cell suspension, adding luteinizing hormone receptor coupled fluorescein to mark testis interstitial cells, and sorting by utilizing flow cytometry to obtain testis interstitial cell suspension; (2) counting by using a blood cell counting plate, diluting the testicular interstitial cells, inoculating the testicular interstitial cells into a 24-pore plate, and culturing the testicular interstitial cells in a cell culture box; and (3) after 24-48 hours, taking out the 24-well plate, discarding cell supernate, cleaning with PBS, adding a uric acid solution, and continuously culturing to obtain the hyperuricemia testicular interstitial cell model. The obtained interstitial cell model can be used for exploring various function change mechanisms of the testicular interstitial cells in a hyperuricemia environment, and is simple to operate, effective, high in repeatability and short in time consumption.

This invention relates to the field of biomedicine, specifically disclosing an antibody for treating benign prostatic hyperplasia (BPH) and its applications. The antibody is a nanobody containing a complementary determinant region (CDR) sequence as shown in SEQ ID NO:5. This invention provides a method for preparing the antibody and demonstrates that it effectively antagonizes the binding of GnRH to GnRHR, thereby inhibiting cAMP production mediated by the GnRH signaling pathway and reducing the levels of testosterone, dihydrotestosterone, and luteinizing hormone. In vivo pharmacodynamic experiments show that the antibody provided by this invention can significantly improve the prostate weight / body weight ratio in a rat model of benign prostatic hyperplasia, exhibiting a good therapeutic effect on BPH and providing a new candidate drug for the clinical treatment of BPH.

The invention relates to an ovary-targeted fumaric acid-based MOFs (Metal-Organic Frameworks) material as well as a preparation method and application thereof. The ovary-targeted fumaric acid-based MOFs material comprises a cerium fumarate metal organic framework serving as a substrate and luteinizing hormone polypeptide grafted on the surface of the substrate, wherein the luteinizing hormone polypeptide is grafted on the surface of the cerium fumarate metal organic framework through an amide condensation reaction and is used for targeting an ovarian tissue; the mass ratio of the luteinizing hormone polypeptide to the cerium fumarate metal organic framework is (0.05-2): 10; and the particle size of the ovary targeting fumaric acid-based MOFs material is 200 to 400 nm. Compared with the prior art, the ovarian targeting fumaric acid-based MOFs material prepared by the invention has the advantages of simple synthesis process, low cost, easiness in batch production, good treatment effect, excellent biocompatibility, dispersion stability and in-vivo safety, capability of targeting ovarian tissues, capability of retarding oxidative stress and inflammation of focus parts, and wide application prospect. Excellent clinical application prospects are realized in the field of biological medicines.

The present invention relates to a liquid pharmaceutical cetrolix composition comprising a stabilizer selected from the group consisting of poloxamer having an average molecular weight of 7,000-12,000 g / mol and / or benzyl alcohol, and a pharmaceutical dosage form comprising the liquid pharmaceutical composition, and their use in inhibiting premature luteinizing hormone surge in a woman undergoing controlled ovarian stimulation. Furthermore, a method for preparing a liquid pharmaceutical cetrolix composition and a pharmaceutical dosage form is disclosed.

The invention relates to a culture regulation and control method for regulating and controlling late propagation of mandarin fish in autumn, and belongs to the field of artificial fish propagation in an aquaculture technology. The method comprises the following steps: (1) spawning induction in spring: injecting high-dose single oxytocin into mandarin fish parents; (2) completing partial oviposition under the action of high-dose single oxytocin, and realizing that the average oviposition amount of each female fish is 20-30% of the theoretical brood amount in spring; (3) carrying out bait control management from spawning to the end of June, reducing the feeding amount, and enabling the oviposition to be in a nutrition state of maintaining or slowly growing; (4) from July to August, carrying out nutrient enrichment cultivation, and recovering sufficient feeding in a period of time before formal spawning induction so as to promote rapid secondary development of gonads of the parent mandarin fish; spawning induction hormone is injected according to a conventional effective dose, artificial fertilization of the parent mandarin fish is induced, concentrated spawning is achieved, and the average spawning amount of each female fish is 80%-90% of the brood amount in autumn. According to the method, the mandarin fish parents can be used for two purposes in one year only through conventional hormone injection and feed management.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and preparation and application thereof. The composition provided by the present application comprises Ramulus cinnamomi, Poria cocos, Cortex moutan, Semen persicae, Radix paeoniae alba, Radix rubiae, Cornus officinalis, and Rhizoma sparganii. The composition can obviously reduce the prostate index and prostate epithelial thickness of a benign prostatic hyperplasia model rat, and relieve interstitial edema. The experimental results show that the composition can obviously reduce the content of dihydrotestosterone, estradiol, testosterone, gonadotropin-releasing hormone, and rat luteinizing hormone in the prostate serum of a model mouse, and increase the content of follicle-stimulating hormone. The above results show that the traditional Chinese medicine composition can inhibit sex hormone disorder, and has the effect of treating prostatic hyperplasia.

A method for enhancing artificial insemination (AI) in mammals, particularly bovine livestock, uses a specialized aqueous mastic solution to substantially increase conception success rates from conventional 60-65% to about 95%. The solution comprises ionic minerals including magnesium chloride, calcium chloride, sodium, potassium, and an emulsion of milled mastic gum (Pistacia lentiscus, preferably Chios Mastiha, particulates 15-40 μm) dissolved in water sourced from inland saltwater bodies such as the Great Salt Lake, delivering approximately 72 ionic and trace minerals. The process involves: preparing the uterus by depositing the solution via syringe to maintain pH at 7.35-7.45 and eliminate bacteria; washing donor semen in the solution to isolate healthy, motile sperm and remove debris / reactive elements; and depositing the washed semen directly into the uterus during ovulation, confirmed via luteinizing hormone detection, ultrasound, or chorionic gonadotropin induction.

This invention relates to a stable parenteral dosage form having a sterile, stable aqueous solution of cetrorelix acetate for immediate injection. The invention also relates to an injection device pre-filled with a sterile, stable aqueous solution of cetrorelix acetate for immediate injection. This invention relates to a method for inhibiting premature luteinizing hormone surges in women undergoing controlled ovarian stimulation, comprising a stable parenteral dosage form having a sterile, stable aqueous solution of cetrorelix acetate for immediate injection.